[{"id":"fe6e795f-22fd-4cd7-b9e7-1f7eb8efecb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06700070","created_at":"2025-02-26T12:47:00.042Z","updated_at":"2025-02-26T12:47:00.042Z","phase":"Phase 1","brief_title":"A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors","source_id_and_acronym":"NCT06700070","lead_sponsor":"Pure Biologics S.A.","biomarkers":" TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["TNFA • CASP3 • GZMB • CD86"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-11-21"},{"id":"245ed9e1-ca34-4788-8cc3-6546ba073450","acronym":"","url":"https://clinicaltrials.gov/study/NCT06573398","created_at":"2025-02-27T08:15:39.768Z","updated_at":"2025-02-27T08:15:39.768Z","phase":"Phase 2","brief_title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","source_id_and_acronym":"NCT06573398","lead_sponsor":"Ruijin Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":"","alterations":" ","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-08-27"},{"id":"9d91719c-a4f8-489a-a4f8-f503e0f382e7","acronym":"PBL-0405-01","url":"https://clinicaltrials.gov/study/NCT06273852","created_at":"2024-02-23T16:26:42.227Z","updated_at":"2024-07-02T16:35:03.110Z","phase":"Phase 1","brief_title":"A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors","source_id_and_acronym":"NCT06273852 - PBL-0405-01","lead_sponsor":"Pure Biologics S.A.","biomarkers":" ROR1 • TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["ROR1 • TNFA • CASP3 • GZMB • CD86"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/29/2024","start_date":" 04/29/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-17"},{"id":"8c229a43-88ef-4aa6-9cca-dad9d1af3b1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457142","created_at":"2021-01-18T17:02:40.865Z","updated_at":"2025-02-25T14:38:10.967Z","phase":"Phase 2","brief_title":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","source_id_and_acronym":"NCT03457142","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • CD28 • CD86","pipe":" | ","alterations":" CD28 expression • IL6 expression","tags":["IL6 • CD28 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • Orencia (abatacept)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/11/2018","start_date":" 09/11/2018","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-05-16"},{"id":"b8813467-068d-4010-8e2e-a3efe97a80e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02379377","created_at":"2021-01-18T11:20:05.224Z","updated_at":"2024-07-02T16:35:05.006Z","phase":"Phase 1","brief_title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","source_id_and_acronym":"NCT02379377","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD163 • CASP3 • CD86","pipe":"","alterations":" ","tags":["CD163 • CASP3 • CD86"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-08"},{"id":"f003bb6c-5459-49c1-947d-35ec28b1d2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135079","created_at":"2024-02-23T15:25:03.657Z","updated_at":"2024-07-02T16:35:04.833Z","phase":"","brief_title":"Immune Profiling in Multiple Myeloma","source_id_and_acronym":"NCT04135079","lead_sponsor":"Mario Boccadoro","biomarkers":" PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-08"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"3a511d5d-3245-4fbd-a2c8-a89db4e723ed","acronym":"CIFRA","url":"https://clinicaltrials.gov/study/NCT03874026","created_at":"2021-01-18T19:06:05.689Z","updated_at":"2024-07-02T16:35:12.803Z","phase":"Phase 2","brief_title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","source_id_and_acronym":"NCT03874026 - CIFRA","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression","tags":["KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 05/19/2023","primary_completion_date":" 05/19/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-03-26"},{"id":"5f31eade-11f2-4c8a-bd77-1e3a256fbe11","acronym":"ETCTN-9844","url":"https://clinicaltrials.gov/study/NCT02453620","created_at":"2021-01-18T11:46:08.614Z","updated_at":"2024-07-02T16:35:13.667Z","phase":"Phase 1","brief_title":"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer","source_id_and_acronym":"NCT02453620 - ETCTN-9844","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • CD86","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Jingzhuda (entinostat) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/12/2016","start_date":" 02/12/2016","primary_txt":" Primary completion: 04/22/2021","primary_completion_date":" 04/22/2021","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-03-20"},{"id":"3e645071-4216-4aec-a0bd-0e6e40f1d02a","acronym":"S1607","url":"https://clinicaltrials.gov/study/NCT02965716","created_at":"2021-01-18T14:34:36.597Z","updated_at":"2024-07-02T16:35:26.748Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT02965716 - S1607","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86","pipe":" | ","alterations":" CD8 expression","tags":["TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 11/05/2024","study_completion_date":" 11/05/2024","last_update_posted":"2023-12-08"},{"id":"495ae210-14e3-4dc2-9bda-5e696bcb61a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056804","created_at":"2023-11-19T01:16:40.961Z","updated_at":"2024-07-02T16:35:28.894Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","source_id_and_acronym":"NCT06056804","lead_sponsor":"Beijing Friendship Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":" | ","alterations":" CD163 expression • CD4 expression","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • capecitabine • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-11-17"},{"id":"64bcff1a-9d20-4e04-9f94-a4766a342655","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062602","created_at":"2023-10-02T20:12:31.941Z","updated_at":"2025-02-25T14:52:38.229Z","phase":"Phase 1","brief_title":"PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC","source_id_and_acronym":"NCT06062602","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CASP3 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • 5-fluorouracil • dazostinag (TAK-676)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 11/15/2022","study_completion_date":" 11/15/2022","last_update_posted":"2023-10-06"},{"id":"ded56621-91d5-4fd3-83a0-0e173411e008","acronym":"","url":"https://clinicaltrials.gov/study/NCT05519397","created_at":"2022-08-29T13:03:09.156Z","updated_at":"2024-07-02T16:35:37.582Z","phase":"","brief_title":"Evaluation of the Role of Immune Checkpoints in Response to Breast Cancer Neoadjuvant Therapy","source_id_and_acronym":"NCT05519397","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • PD-L2 • HAVCR2 • IL2RA • CD27 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • PD-L2 • HAVCR2 • IL2RA • CD27 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2023-09-11"},{"id":"a06b4240-2997-4ef2-a868-1a44f43ce1b2","acronym":"MK-3475-C99","url":"https://clinicaltrials.gov/study/NCT05159778","created_at":"2021-12-16T13:53:29.380Z","updated_at":"2025-02-25T16:17:03.472Z","phase":"Phase 2","brief_title":"Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)","source_id_and_acronym":"NCT05159778 - MK-3475-C99","lead_sponsor":"HiberCell, Inc.","biomarkers":" HER-2 • PD-L1 • ER • PIK3CA • PGR • CD86","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2 • PD-L1 • ER • PIK3CA • PGR • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 11/09/2021","start_date":" 11/09/2021","primary_txt":" Primary completion: 03/22/2023","primary_completion_date":" 03/22/2023","study_txt":" Completion: 04/12/2023","study_completion_date":" 04/12/2023","last_update_posted":"2023-06-22"},{"id":"4e0dcd1c-8c10-406d-8fe8-6a396d1d3f85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457075","created_at":"2022-07-13T11:56:50.702Z","updated_at":"2024-07-02T16:35:48.571Z","phase":"","brief_title":"Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer","source_id_and_acronym":"NCT05457075","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2023-05-09"},{"id":"23e94fe6-5db5-4814-8780-12a2c9a9dde5","acronym":"ENDURE-CML-IX","url":"https://clinicaltrials.gov/study/NCT03117816","created_at":"2021-04-28T11:52:33.963Z","updated_at":"2024-07-02T16:35:51.664Z","phase":"Phase 3","brief_title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","source_id_and_acronym":"NCT03117816 - ENDURE-CML-IX","lead_sponsor":"Philipps University Marburg Medical Center","biomarkers":" ABL1 • BCR • PD-1 • IL6 • IL10 • CD86","pipe":"","alterations":" ","tags":["ABL1 • BCR • PD-1 • IL6 • IL10 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besremi (ropeginterferon alfa-2b-njft)"],"overall_status":"Completed","enrollment":" Enrollment 214","initiation":"Initiation: 05/04/2017","start_date":" 05/04/2017","primary_txt":" Primary completion: 01/26/2022","primary_completion_date":" 01/26/2022","study_txt":" Completion: 12/12/2022","study_completion_date":" 12/12/2022","last_update_posted":"2023-03-31"},{"id":"d503b483-0df6-4db7-b6c7-c7c27120a653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05460702","created_at":"2022-07-15T16:05:37.936Z","updated_at":"2024-07-02T16:35:55.359Z","phase":"","brief_title":"Relationship Between Breast Cancer Subtypes and Immune Checkpoints","source_id_and_acronym":"NCT05460702","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2023-02-16"},{"id":"be7449e1-1a9b-46c1-af26-11ab58c0f0ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04540159","created_at":"2021-01-18T21:43:27.578Z","updated_at":"2024-07-02T16:35:59.572Z","phase":"","brief_title":"Immune Checkpoints in Intraabdominal Ascites Fluid","source_id_and_acronym":"NCT04540159","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • TGFB1 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • TGFB1 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-12-06"},{"id":"edbfae7e-f72f-4206-b13c-5cf6d41d84b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566848","created_at":"2021-01-18T21:48:53.808Z","updated_at":"2024-07-02T16:35:59.565Z","phase":"","brief_title":"The Status of Immune Checkpoints at Gastrointestinal Cancer","source_id_and_acronym":"NCT04566848","lead_sponsor":"Istanbul Training and Research Hospital","biomarkers":" PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • TGFB1 • CD86 • ISG20 • LGALS9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3 • CTLA4 • HAVCR2 • IL2RA • TGFB1 • CD86 • ISG20 • LGALS9"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2022-12-06"},{"id":"d45ba617-287d-4d20-b7f9-60232b733564","acronym":"","url":"https://clinicaltrials.gov/study/NCT04065555","created_at":"2021-02-12T16:54:14.811Z","updated_at":"2025-02-25T14:51:31.104Z","phase":"Phase 1","brief_title":"Intratumoral Microdosing of TAK-981 in Head and Neck Cancer","source_id_and_acronym":"NCT04065555","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Bavencio (avelumab) • subasumstat (TAK-981)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 06/20/2022","primary_completion_date":" 06/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2022-07-29"},{"id":"01bab055-3bba-471a-9ff9-022c1458fb21","acronym":"","url":"https://clinicaltrials.gov/study/NCT04891718","created_at":"2021-05-18T12:02:12.873Z","updated_at":"2025-02-25T14:59:52.160Z","phase":"Phase 1","brief_title":"CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia","source_id_and_acronym":"NCT04891718","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • TAK-186"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 06/05/2022","primary_completion_date":" 06/05/2022","study_txt":" Completion: 06/05/2022","study_completion_date":" 06/05/2022","last_update_posted":"2022-07-08"},{"id":"46c08f17-26c5-4730-b84c-c4364ca8da5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02545361","created_at":"2021-01-19T08:29:28.970Z","updated_at":"2024-07-02T16:37:07.837Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients","source_id_and_acronym":"NCT02545361","lead_sponsor":"Kahr Medical","biomarkers":" FAS • CD80 • CD86","pipe":"","alterations":" ","tags":["FAS • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KAHR-102 • dexamethasone injection"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2018-08-16"},{"id":"695a8f0a-8022-4d0c-9439-2ec7fd2bbea6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00607048","created_at":"2021-01-18T02:15:12.023Z","updated_at":"2024-07-02T16:37:24.096Z","phase":"Phase 1","brief_title":"Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors","source_id_and_acronym":"NCT00607048","lead_sponsor":"Hoffmann-La Roche","biomarkers":" IL6 • TNFA • ICAM1 • CD40 • CD86 • FCER2","pipe":"","alterations":" ","tags":["IL6 • TNFA • ICAM1 • CD40 • CD86 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • CP-870893"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 07/01/2009","study_completion_date":" 07/01/2009","last_update_posted":"2017-03-27"}]